Lv11
40 积分 2022-12-09 加入
Development Strategy for Innovation System of Radiopharmaceuticals in China
2小时前
求助中
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
2个月前
已完结
The impact of external innovation on new drug approvals: A retrospective analysis
2个月前
已完结
The Withdrawal of Drugs for Commercial Reasons
3个月前
已完结
Monoclonal antibody based radiopharmaceuticals for imaging and therapy
3个月前
已完结
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow’s Guide in the Clinic
3个月前
已完结
Lung cancer
3个月前
已完结
Correction to abstract title “Efficacy and safety of [177Lu]Lu‐edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial”
4个月前
已完结
Antibodies to watch in 2025
4个月前
已完结
皖公网安备34019202002308
